title: Multidrug resistant tuberculosis.
authors.affiliation: Brighton and Sussex Medical School, Brighton, UK.
authors.forename: James
authors.initials: J
authors.lastname: Millard
authors.affiliation: Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
authors.forename: Cesar
authors.initials: C
authors.lastname: Ugarte-Gil
authors.affiliation: TB Centre, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK David.moore@lshtm.ac.uk.
authors.forename: David A J
authors.initials: DA
authors.lastname: Moore
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005544:Forecasting; D005838:Genotype; D014943:Global Health; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D010166:Palliative Care; D010641:Phenotype; D011379:Prognosis; D011634:Public Health; D012293:Rifampin / Q000627:therapeutic use; D012307:Risk Factors; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin